Adele, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Adele, Maintenance, and What Happens If You Stop

What Adele Has Actually Said

Between 2019 and 2021, Adele underwent a widely documented physical transformation. In a November 2021 interview with Oprah Winfrey on CBS, she described the change as rooted in exercise, particularly weight training, and credited fitness with helping her manage anxiety. She told British Vogue in October 2021 that working out became a coping mechanism during her divorce, not a weight-loss program.

At no point has Adele publicly confirmed using semaglutide, tirzepatide, liraglutide, or any other GLP-1 receptor agonist. Her trainer, Dalton Wong, has spoken publicly about her regimen, which centered on circuit training and Pilates. The Sirtfood diet, which she reportedly followed in the early phase of her weight loss, restricts calories to 1,000 to 1,500 kcal per day while emphasizing foods rich in sirtuin-activating polyphenols (kale, dark chocolate, green tea, red wine in small amounts).

The HealthRX Medical Team position is straightforward: speculation about a celebrity's medication use is not evidence. Adele says she changed her lifestyle. We take that at face value.

At a glance

  • Public record: Adele credits the Sirtfood diet, exercise (circuit training, Pilates), and mental health work for her weight loss
  • GLP-1 connection: publicly speculated, not confirmed by Adele or her representatives
  • Clinical focus of this page: GLP-1 discontinuation science, weight regain data, and maintenance protocols
  • Why it matters: Adele's timeline (2019 to 2021) predates the mainstream GLP-1 conversation, making her case a useful comparison point for lifestyle-only vs. pharmacological weight management

Why the GLP-1 Speculation Persists

The speed and magnitude of Adele's weight loss (reported at roughly 100 pounds) triggered public comparisons to results seen with GLP-1 receptor agonists. After semaglutide 2.4 mg (Wegovy) received FDA approval for chronic weight management in June 2021, celebrity weight-loss stories were increasingly filtered through a pharmacological lens.

The HealthRX Medical Team notes a pattern worth examining. The public tends to apply a binary frame: either someone used a drug or they didn't. Clinical reality is more textured. Lifestyle interventions alone can produce significant weight loss. A 2011 meta-analysis in Obesity Reviews found that structured diet-plus-exercise programs yielded mean losses of 5 to 8% of body weight at 12 months, with some individuals losing substantially more. Caloric restriction to 1,000 kcal/day, as some phases of the Sirtfood diet prescribe, will produce rapid early losses in most people.

Whether Adele's results are consistent with lifestyle alone or suggest pharmacological assistance is a question no outside observer can answer definitively. What we can do is examine the clinical literature on what happens when GLP-1 therapy stops, because that question affects the millions of confirmed users now weighing long-term decisions.

The Discontinuation Problem: Clinical Data

GLP-1 receptor agonists suppress appetite through multiple mechanisms. They slow gastric emptying, act on hypothalamic satiety centers, and reduce food-reward signaling in the brain. These effects are dose-dependent and, critically, they are not permanent.

The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, followed participants after they stopped semaglutide 2.4 mg. The findings were stark. Participants regained approximately two-thirds of the weight they had lost within one year of discontinuation. Mean body weight had decreased by 17.3% during the 68-week treatment period. One year after stopping, only about 5.6% of the original loss was maintained.

The SURMOUNT-4 trial for tirzepatide, published in JAMA in 2023, showed a similar pattern. Participants who switched from tirzepatide to placebo regained roughly half of their lost weight over 52 weeks. Those who continued treatment maintained or extended their losses.

These results are consistent across the GLP-1 class. A 2023 systematic review in Obesity confirmed that weight regain after GLP-1 discontinuation is the norm, not the exception. The median regain across studies was 60 to 70% of lost weight within 12 months of stopping.

Why Weight Returns: The Biology

Weight regain after GLP-1 discontinuation is not a failure of willpower. It reflects the reactivation of biological systems that defend a higher body weight set point.

When someone loses a significant amount of weight by any method, the body mounts a coordinated counter-response. Levels of ghrelin (the hunger hormone) increase, while leptin and peptide YY decrease. Resting metabolic rate drops beyond what would be predicted by the loss of lean mass alone, a phenomenon called metabolic adaptation or adaptive thermogenesis. These changes persist for years.

GLP-1 receptor agonists override many of these compensatory mechanisms while active. They blunt ghrelin signaling, enhance satiety peptide release, and reduce the hedonic drive to eat. When the drug is withdrawn, these protective effects disappear. The underlying biological pressure to regain weight, which was always present, reasserts itself.

The HealthRX Medical Team considers this the most important concept in modern obesity pharmacology. GLP-1 medications treat an ongoing biological condition. Stopping them is physiologically comparable to stopping antihypertensive medication in a patient whose blood pressure is controlled: the underlying condition has not resolved.

Maintenance Without Medication: What Works

For individuals who lose weight through lifestyle changes alone (as Adele reports), the maintenance challenge is real but follows a different trajectory. A meta-analysis in the American Journal of Clinical Nutrition found that successful long-term maintainers share several behavioral patterns: high levels of physical activity (200+ minutes per week), consistent dietary monitoring, and regular self-weighing.

Data from the National Weight Control Registry shows that people who maintain a loss of 30 or more pounds for at least a year report burning roughly 2,600 kcal per week through exercise. Adele's reported regimen of intensive circuit training and Pilates sessions fits this profile.

The clinical distinction matters. Weight lost through caloric restriction and exercise, while still subject to metabolic adaptation, does not face the abrupt pharmacological withdrawal that GLP-1 discontinuation creates. The compensatory hunger surge after stopping semaglutide has no direct parallel in diet-based weight loss, where appetite changes are more gradual.

Dose Tapering and Emerging Strategies

The question of whether GLP-1 dose reduction (rather than complete cessation) can preserve weight loss is an active area of research. Some clinicians are exploring maintenance doses lower than the therapeutic maximum. Semaglutide's approved doses range from 0.25 mg to 2.4 mg weekly, and there is early clinical interest in whether a lower maintenance dose (e.g., 0.5 mg or 1.0 mg) can sustain weight loss while reducing side effects and cost.

The STEP 5 trial demonstrated that continued semaglutide at 2.4 mg over two years maintained a 15.2% weight reduction, suggesting that chronic use preserves efficacy. But no large randomized trial has yet tested a formal step-down protocol.

The HealthRX Medical Team recommends that any decision to taper or discontinue a GLP-1 medication be made with a prescribing clinician, with a structured plan that includes intensified behavioral support and metabolic monitoring during the transition.

The Adele Comparison: Why It Resonates

Adele's weight loss story became a public reference point for the GLP-1 era despite predating it. Her case sits at a cultural intersection. If she achieved her results without pharmacological support, her experience represents what structured lifestyle change can accomplish. If GLP-1 speculation were ever confirmed (and there is no evidence supporting this), her sustained maintenance would be notable given the discontinuation data.

Either way, the comparison illuminates a genuine clinical tension. Lifestyle-based weight management and pharmacological weight management produce overlapping results on the scale, but they involve different physiological mechanisms, different maintenance requirements, and different risk profiles.

The public conversation around Adele often collapses these distinctions. The HealthRX Medical Team view is that both pathways are valid medical approaches, and neither should be stigmatized. Obesity is a chronic disease with genetic, hormonal, and environmental drivers. Some patients will respond to behavioral intervention alone. Others will require long-term pharmacotherapy. The right approach depends on individual biology, not celebrity comparison.

What to Discuss with Your Clinician

If you are currently taking a GLP-1 receptor agonist and considering stopping, the HealthRX Medical Team recommends bringing these questions to your provider:

  • Has my metabolic profile improved enough to attempt a supervised taper?
  • What behavioral supports should be in place before and during discontinuation?
  • Am I a candidate for a reduced maintenance dose rather than full cessation?
  • What monitoring (weight, HbA1c, lipid panel) should continue post-discontinuation?
  • What is the restart protocol if significant regain occurs?

These conversations are especially important for patients with type 2 diabetes, where GLP-1 withdrawal can affect glycemic control beyond weight alone.

Frequently asked questions

›
›
›
›
›

References